Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Psychiatric Emergencies, The Neuroleptic Malignant and Serotonin Syndromes
Emerg Med Clin North Am 18:317-325, Carbone,J.R., 2000
Criteria for the Diagnosis of Corticobasal Degeneration
Neurol 80:496-503, Armstrong, M.J.,et al, 2013
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Malignant Hyperthermia, Update on Susceptibility Testing
JAMA 293:2918-2924,2958, Litman,R.S.&Rosenberg,H., 2005
Clinicopath Conf, Multiple-System Atrophy
NEJM 351:912-921, Case 27-2004, 2004
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Acute, Drug-Induced, Life-Threatening Neurological Syndromes
The Neurologist 4:196-210, Richard,I.H., 1998
Detecting Susceptibility to Malignant Hyperthermia
BMJ 304:791-792, Ellis,F.R., 1992
Missed Neuroleptic Malignant Syndrome
BMJ 304:831-832, Renwick,D.S.,et al, 1992
Neuroleptic-Induced Catatonia as a Stage in the Progression Toward NMS
J Am Acad Child Adolesc Psychiatry 31:1161-1164, Woodbury,M.M.&Woodbury,M.A., 1992
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
Neuroleptic Malignant Syndrome:Review and Analysis of 115 Cases
Biol Psychiatry 22:1004-1020, Addonizio,G.,et al, 1987
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986
The Malignant Hyperthermia Syndrome
NEJM 309:416-418, Nelson,T.E.,et al, 1983
The Neuroleptic Malignant Syndrome
Arch Int Med 142:1183-1185, Smego,R.A.,et al, 1982
Neuroleptic Malignant Syndrome:A Pathogenetic Role for Dopamine Receptor Blockage
Neurol 31:132-137, Henderson,V.W.,et al, 1981